FDA approves Cleviprex; Expression Genetics secures VC funds;

> The FDA has approved Cleviprex--an intravenous blood pressure drug--from The Medicines Company. Story

> Expression Genetics has completed its $12-million Series B financing. The final, $7 million portion of the financing was secured in July. The money will be used to fund the clinical development of its lead product--the cancer therapeutic EGEN-001--and to further advance its development of delivery technologies for siRNA and shRNA. Release

> Affymetrix says it will close its manufacturing facility in West Sacramento and relocate the operations to Singapore. Report

> The new execs taking control at MiddleBrook Pharmaceuticals may move the company from Maryland to Texas. Report

> Los Altos, CA-based Interkrin Therapeutics has secured $18.25 million of a 26.14 million Series C. Story

> Two drugmakers' hometown newspapers offer a rundown on the litigation they face over sales tactics: For AstraZeneca, it's allegations of improperly marketing Seroquel, and for Abbott, more claims over its pricing of the AIDS med Norvir. Report

> Analysts just can't get their minds off which drugmakers might make a deal next. The most recent suspects are Bayer and Onyx, which are partnered on the liver and kidney cancer med Nexavar. Report

> hould HIV drugs be used to prevent infection with the deadly virus? Given the fact that vaccine developers have to start all over on their anti-HIV shot, and microbicides haven't shown much promise either, prophylactic use of antiretroviral drugs seems like a logical choice. Report

> GaxoSmithKline is doing some fancy number-crunching in an attempt to get the U.K. to cover its cancer med Tyverb (sold as Tykerb in the U.S.). According to the Financial Times, GSK is working on a pioneering deal that would cap the cost of Tyverb--no matter how many patients sign on to use it. GSK report

And Finally... Overall, job prospects for new college grads are bleak, but hiring in biotechnology remains strong. Article

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."